Epimab Biotherapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Shanghaichinafounded In 2015The Company Specializes In Developing Multispecific Antibodies Using Proprietary Platforms Like Fit Igaand Mat Fabthese Technologies Enable The Efficient Creation Of Bispecific Antibodies Aimed At Strategic Oncology Areasincluding Tumor Targeting And Immune Cell Engagement Epimab Has A Strong Pipeline Featuring Five Clinical Stage Assets And Over Ten Preclinical Candidatesnotable Clinical Stage Assets Include Emb 01A Bispecific Antibody Targeting Egfr And Cmet For Gastrointestinal Cancersand Emb 06Which Targets Bcma And Cd3 For Multiple Myeloma And Autoimmune Diseasesthe Company Has Established Strategic Partnershipsincluding A License Agreement For Emb 06 With Vignette Bioshowcasing Its Collaborative Approach In Advancing Therapeutic Candidates Led By An Experienced Management Teamepimab Operates Research And Manufacturing Facilities In Shanghai And Suzhoufocusing On Addressing Unmet Medical Needs In Oncology Through Innovative Technologies
